Literature DB >> 26497122

Infiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profile.

Carey A Eberle1, Salvatore Piscuoglio1, Emad A Rakha2, Charlotte K Y Ng1, Felipe C Geyer1,3, Marcia Edelweiss1, Rita A Sakr4, Britta Weigelt1, Jorge S Reis-Filho1, Ian O Ellis2.   

Abstract

AIMS: Infiltrating epitheliosis is a rare complex sclerosing lesion (CSL) of the breast, characterized by infiltrating ducts immersed in a scleroelastotic stroma and filled with cells having architectural and cytological patterns reminiscent of those of usual ductal hyperplasia. In this study we sought to define the molecular characteristics of infiltrating epitheliosis. METHODS AND
RESULTS: Eight infiltrating epitheliosis, adjacent breast lesions (one usual ductal hyperplasia, one papilloma, one micropapillary ductal carcinoma in situ and one low-grade adenosquamous carcinoma), and corresponding normal breast tissue from each case were microdissected and subjected to massively parallel sequencing analysis targeting all coding regions of 254 genes mutated recurrently in breast cancer and/or related to DNA repair. Mutations in components of the PI3K pathway were found in all infiltrating epitheliosis samples, seven of which harboured PIK3CA hotspot mutations, while the remaining case displayed a PIK3R1 somatic mutation.
CONCLUSIONS: Somatic mutations affecting PI3K pathway genes were found to be highly prevalent in infiltrating epitheliosis, suggesting that these lesions may be neoplastic rather than hyperplastic. The landscape of somatic genetic alterations found in infiltrating epitheliosis is similar to that of radial scars/CSLs, suggesting that infiltrating epitheliosis may represent one end of this spectrum of lesions.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  complex sclerosing lesions; immunohistochemistry; infiltrating epitheliosis; massively parallel sequencing

Mesh:

Substances:

Year:  2016        PMID: 26497122      PMCID: PMC4957818          DOI: 10.1111/his.12897

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  41 in total

1.  Phenotypic alterations in myoepithelial cells associated with benign sclerosing lesions of the breast.

Authors:  Justin B Hilson; Stuart J Schnitt; Laura C Collins
Journal:  Am J Surg Pathol       Date:  2010-06       Impact factor: 6.394

2.  Interdependence of radial scar and proliferative disease with respect to invasive breast carcinoma risk in patients with benign breast biopsies.

Authors:  Melinda E Sanders; David L Page; Jean F Simpson; Peggy A Schuyler; W Dale Plummer; William D Dupont
Journal:  Cancer       Date:  2006-04-01       Impact factor: 6.860

3.  Subgross pathologic features and incidence of radial scars in the breast.

Authors:  S R Wellings; C E Alpers
Journal:  Hum Pathol       Date:  1984-05       Impact factor: 3.466

4.  Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions.

Authors:  Megan L Troxell; Alayne L Brunner; Tanaya Neff; Andrea Warrick; Carol Beadling; Kelli Montgomery; Shirley Zhu; Christopher L Corless; Robert B West
Journal:  Mod Pathol       Date:  2012-03-30       Impact factor: 7.842

5.  Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.

Authors:  Charlotte K Y Ng; Anne M Schultheis; Francois-Clement Bidard; Britta Weigelt; Jorge S Reis-Filho
Journal:  J Natl Cancer Inst       Date:  2015-02-23       Impact factor: 13.506

6.  Frequent PIK3CA mutations in radial scars.

Authors:  Katie L Wolters; Daphne Ang; Andrea Warrick; Carol Beadling; Christopher L Corless; Megan L Troxell
Journal:  Diagn Mol Pathol       Date:  2013-12

7.  Radial scars and subsequent breast cancer risk: results from the Nurses' Health Studies.

Authors:  Sarah A Aroner; Laura C Collins; James L Connolly; Graham A Colditz; Stuart J Schnitt; Bernard A Rosner; Susan E Hankinson; Rulla M Tamimi
Journal:  Breast Cancer Res Treat       Date:  2013-04-23       Impact factor: 4.872

8.  Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands.

Authors:  Ilan Weinreb; Salvatore Piscuoglio; Luciano G Martelotto; Daryl Waggott; Charlotte K Y Ng; Bayardo Perez-Ordonez; Nicholas J Harding; Javier Alfaro; Kenneth C Chu; Agnes Viale; Nicola Fusco; Arnaud da Cruz Paula; Caterina Marchio; Rita A Sakr; Raymond Lim; Lester D R Thompson; Simion I Chiosea; Raja R Seethala; Alena Skalova; Edward B Stelow; Isabel Fonseca; Adel Assaad; Christine How; Jianxin Wang; Richard de Borja; Michelle Chan-Seng-Yue; Christopher J Howlett; Anthony C Nichols; Y Hannah Wen; Nora Katabi; Nicholas Buchner; Laura Mullen; Thomas Kislinger; Bradly G Wouters; Fei-Fei Liu; Larry Norton; John D McPherson; Brian P Rubin; Blaise A Clarke; Britta Weigelt; Paul C Boutros; Jorge S Reis-Filho
Journal:  Nat Genet       Date:  2014-09-21       Impact factor: 38.330

9.  Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.

Authors:  Jennifer Dunlap; Claudia Le; Arielle Shukla; Janice Patterson; Ajia Presnell; Michael C Heinrich; Christopher L Corless; Megan L Troxell
Journal:  Breast Cancer Res Treat       Date:  2009-05-06       Impact factor: 4.872

10.  Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.

Authors:  Lucia Hernandez; Paul M Wilkerson; Maryou B Lambros; Adriana Campion-Flora; Daniel Nava Rodrigues; Arnaud Gauthier; Cecilia Cabral; Vidya Pawar; Alan Mackay; Roger A'Hern; Caterina Marchiò; Jose Palacios; Rachael Natrajan; Britta Weigelt; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2012-03-21       Impact factor: 7.996

View more
  6 in total

Review 1.  The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions.

Authors:  Felipe C Geyer; Fresia Pareja; Britta Weigelt; Emad Rakha; Ian O Ellis; Stuart J Schnitt; Jorge S Reis-Filho
Journal:  Am J Pathol       Date:  2017-07-20       Impact factor: 4.307

2.  Tall cell carcinoma with reversed polarity: case report with gene sequencing and literature review.

Authors:  Yufan Wei; Liming Ding; Xin Song; Xia Tian; Ningning Min; Qingyu Guan; Xiru Li; Mei Liu
Journal:  Gland Surg       Date:  2021-11

3.  Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.

Authors:  Mothaffar F Rimawi; Carmine De Angelis; Alejandro Contreras; Fresia Pareja; Felipe C Geyer; Kathleen A Burke; Sabrina Herrera; Tao Wang; Ingrid A Mayer; Andres Forero; Rita Nanda; Matthew P Goetz; Jenny C Chang; Ian E Krop; Antonio C Wolff; Anne C Pavlick; Suzanne A W Fuqua; Carolina Gutierrez; Susan G Hilsenbeck; Marilyn M Li; Britta Weigelt; Jorge S Reis-Filho; C Kent Osborne; Rachel Schiff
Journal:  Breast Cancer Res Treat       Date:  2017-11-07       Impact factor: 4.872

4.  Next generation sequencing of the nidus of early (adenosquamous proliferation rich) radial sclerosing lesions of the breast reveals evidence for a neoplastic precursor lesion.

Authors:  Mark J Wilsher; Thomas W Owens; Richard Jn Allcock
Journal:  J Pathol Clin Res       Date:  2017-03-20

Review 5.  Multiple Papillomas of the Breast: A Review of Current Evidence and Challenges.

Authors:  Rossella Rella; Giovanna Romanucci; Damiano Arciuolo; Assunta Scaldaferri; Enida Bufi; Sebastiano Croce; Andrea Caulo; Oscar Tommasini
Journal:  J Imaging       Date:  2022-07-13

6.  Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort.

Authors:  John R Lozada; Thais Basili; Fresia Pareja; Barbara Alemar; Arnaud Da Cruz Paula; Rodrigo Gularte-Merida; Dilip D Giri; Patricia Querzoli; Gabor Cserni; Emad A Rakha; Maria P Foschini; Jorge S Reis-Filho; Edi Brogi; Britta Weigelt; Felipe C Geyer
Journal:  Histopathology       Date:  2018-06-01       Impact factor: 7.778

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.